Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Merck (NYSE:MRK) recently announced the FDA's priority review for an sBLA for WINREVAIR™ and results from its ZENITH trial, showcasing significant improvements in pulmonary arterial hypertension ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

US pharma giant Merck & Co today revealed that the US Food and Drug Administration (FDA) has accepted and granted priority ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Rahway, New Jersey Thursday, July 3, 2025, 09:00 Hrs [IST] ...

Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study ...

Investing.com - Merck (NYSE:MRK), a prominent player in the pharmaceuticals industry with a market cap of $198.5 billion, saw its stock rise Monday after announcing positive topline results from ...